Org OD 14 and the endometrium
Other
OA: closed
CC0
⤵ 14 in-corpus citations
AI-generated summary
This paper investigates the effects of Org OD 14 on the endometrium.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Long-term therapy with (7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14; tibolone, Livial) has no influence on the endometrium in post-menopausal women. This was concluded from endometrial biopsies taken from 39 post-menopausal women treated with 2.5 mg/day for periods of from 3 months to 5 years 11 months at three centres. These results accord with the data published so far on 129 women who have been treated for up to 2 years. A review of the data relating to a total of 168 patients treated with Org OD 14 is presented. The endometrial pattern observed at the start of therapy showed no change during treatment in 90% of patients. In 15 cases slight proliferation was apparent after treatment, this being a similar pattern to that seen in the initial days of a normal cycle. In a considerable number of patients no tissue could be obtained, indicating an atrophic pattern. The picture following Org OD 14 therapy was the same as that observed in untreated normal post-menopausal women.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (15)
- W45007598 via openalex
- W1976445188 via openalex
- W1984955008 via openalex
- W2018671276 via openalex
- W2028752503 via openalex
- W2030908961 via openalex
- W2048182846 via openalex
- W2053127900 via openalex
- W2060066965 via openalex
- W2081496304 via openalex
- W2086684542 via openalex
- W2087306228 via openalex
- W2127857303 via openalex
- W2150150420 via openalex
- W2415486290 via openalex
Cited by (12)
- De novo postmenopausal endometriosis during tibolone treatment: a case report and review of the literature 2007
- Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestagen 2006
- Effects of tibolone on the endometrium 2001
- Long term effects of tibolone on the genital tract in postmenopausal women 1999
- Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis 1997
- Microscopic evaluation of the effect of hormone replacement therapy on the endometrium in women who bleed 1997
- Failure of tibolone to control hypoestrogenic symptoms in premenopausal women undergoing hysterectomy and bilateral salpingoophorectomy 1997
- Immunohistochemical and hysteroscopic assessment of postmenopausal women with uterine bleeding whilst taking Tibolone 1996
- Immunohistochemical and hysteroscopic assessment of postmenopausal women with uterine bleeding whilst taking Tibolone 1996
- The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl) 1996
- Exacerbation of adenomyosis in a postmenopausal woman taking tibolone associated with an elevation in serum CA 125 1994
- New drugs and new uses for existing drugs which act on the uterus: Gynaecology 1992
Source provenance
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-10-08T21:06:31.728877+00:00
- unpaywall
- last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0
· commercial use OK